These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 15200443

  • 1. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy?
    Kronenberg F, Lingenhel A, Lhotta K, Rantner B, Kronenberg MF, König P, Thiery J, Koch M, von Eckardstein A, Dieplinger H.
    Kidney Int; 2004 Jul; 66(1):348-54. PubMed ID: 15200443
    [Abstract] [Full Text] [Related]

  • 2. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
    Attman PO, Samuelsson OG, Moberly J, Johansson AC, Ljungman S, Weiss LG, Knight-Gibson C, Alaupovic P.
    Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
    [Abstract] [Full Text] [Related]

  • 3. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome.
    Wanner C, Rader D, Bartens W, Krämer J, Brewer HB, Schollmeyer P, Wieland H.
    Ann Intern Med; 1993 Aug 15; 119(4):263-9. PubMed ID: 8328733
    [Abstract] [Full Text] [Related]

  • 4. The effect of change of renal replacement therapy on serum lipoprotein (a) concentration.
    Misra M, Webb AT, Reaveley DA, Doherty E, O'Donnell M, Seed M, Brown EA.
    Adv Perit Dial; 1997 Aug 15; 13():168-73. PubMed ID: 9360675
    [Abstract] [Full Text] [Related]

  • 5. Lipoprotein(a) in patients with the nephrotic syndrome: influence of immunosuppression and proteinuria.
    Wanner C, Bartens W, Nauck M, Zäuner I, Greiber S, Schollmeyer P.
    Miner Electrolyte Metab; 1996 Aug 15; 22(1-3):26-30. PubMed ID: 8676820
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.
    Artemeva NV, Safarova MS, Ezhov MV, Afanasieva OI, Dmitrieva OA, Pokrovsky SN.
    Atheroscler Suppl; 2015 May 15; 18():53-8. PubMed ID: 25936305
    [Abstract] [Full Text] [Related]

  • 8. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
    Milionis HJ, Elisaf MS, Karabina SA, Bairaktari E, Tselepis AD, Siamopoulos KC.
    Kidney Int; 1999 Dec 15; 56(6):2276-85. PubMed ID: 10594806
    [Abstract] [Full Text] [Related]

  • 9. Lipoprotein(a) levels in relation to albumin concentration in childhood nephrotic syndrome.
    Noto D, Barbagallo CM, Cascio AL, Cefalù AB, Cavera G, Caldarella R, Marino G, Travali S, Cutaia I, Maringhini S, Notarbartolo A, Averna M.
    Kidney Int; 1999 Jun 15; 55(6):2433-9. PubMed ID: 10354292
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure.
    Milionis HJ, Elisaf MS, Tselepis A, Bairaktari E, Karabina SA, Siamopoulos KC.
    Am J Kidney Dis; 1999 Jun 15; 33(6):1100-6. PubMed ID: 10352198
    [Abstract] [Full Text] [Related]

  • 13. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
    Berneis K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I, Spinas GA, Carmina E.
    Int J Clin Pract; 2009 Jan 15; 63(1):56-62. PubMed ID: 19125993
    [Abstract] [Full Text] [Related]

  • 14. Dyslipidemia and nephrotic syndrome: recent advances.
    Kronenberg F.
    J Ren Nutr; 2005 Apr 15; 15(2):195-203. PubMed ID: 15827892
    [Abstract] [Full Text] [Related]

  • 15. Lipoprotein(a) levels are increased in healthy young subjects with parental history of premature myocardial infarction.
    Gaeta G, Cuomo S, Capozzi G, Foglia MC, Barra S, Madrid A, Stornaiuolo V, Trevisan M.
    Nutr Metab Cardiovasc Dis; 2008 Sep 15; 18(7):492-6. PubMed ID: 17962002
    [Abstract] [Full Text] [Related]

  • 16. Evidence of dependence of lipoprotein(a) on triglyceride and high-density lipoprotein metabolism.
    Konerman M, Kulkarni K, Toth PP, Jones SR.
    J Clin Lipidol; 2012 Sep 15; 6(1):27-32. PubMed ID: 22264571
    [Abstract] [Full Text] [Related]

  • 17. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.
    Pennell P, Leclercq B, Delahunty MI, Walters BA.
    Clin Nephrol; 2006 Nov 15; 66(5):336-47. PubMed ID: 17140163
    [Abstract] [Full Text] [Related]

  • 18. The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome.
    Kronenberg F, Lingenhel A, Lhotta K, Rantner B, Kronenberg MF, König P, Thiery J, Koch M, von Eckardstein A, Dieplinger H.
    Kidney Int; 2004 Feb 15; 65(2):606-12. PubMed ID: 14717931
    [Abstract] [Full Text] [Related]

  • 19. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a).
    Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ.
    JAMA; 1995 Dec 13; 274(22):1771-4. PubMed ID: 7500507
    [Abstract] [Full Text] [Related]

  • 20. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.
    Joy MS, Dornbrook-Lavender KA, Chin H, Hogan SL, Denu-Ciocca C.
    Ann Pharmacother; 2008 Jan 13; 42(1):9-15. PubMed ID: 18000162
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.